Tirzepatide GLP-1/GIP Dual Agonist

Tirzepatide is a dual GLP-1/GIP receptor agonist developed by Eli Lilly and approved by the FDA for both type 2 diabetes (as Mounjaro) and chronic weight management (as Zepbound). It represents a significant advancement over single-receptor GLP-1 medications because it simultaneously targets two key metabolic hormones involved in appetite regulation, insulin secretion, and fat metabolism.

The dual mechanism creates a synergistic effect. The GLP-1 component reduces appetite, slows gastric emptying, and improves insulin sensitivity — the same mechanisms as semaglutide. The GIP component adds a powerful second dimension: glucose-dependent insulinotropic polypeptide enhances glucose-stimulated insulin secretion, improves fat metabolism in adipose tissue, increases energy expenditure, and may promote the conversion of white fat to metabolically active brown fat that burns more calories at rest.

In the landmark SURMOUNT-1 trial published in the New England Journal of Medicine (2022), participants receiving the highest dose of tirzepatide (15mg) reported a 22.5% average body weight reduction over 72 weeks — among the highest weight loss recorded for an FDA-approved medication at that time. About 96% of participants reported losing at least 5% of their body weight. These figures describe what researchers observed in that trial, not results we offer.

The SURPASS clinical trial program compared tirzepatide to semaglutide head-to-head, reporting greater A1C reduction (up to 2.4%) and weight loss in participants with type 2 diabetes. This dual metabolic profile is part of why tirzepatide is often discussed for people with both obesity and diabetes or prediabetes.

To put the trial figures in context: an 18–22% reduction for a 200-pound individual would be roughly 36–44 pounds. Trials also reported improvements in blood pressure, triglycerides, liver fat, and inflammatory markers. These are trial observations, not results GLP3 Weight Loss offers or promises. Only an independent licensed provider can decide whether tirzepatide is appropriate for you.

• Drug class — GLP-1/GIP dual receptor agonist
• Regulatory status — FDA-approved (Mounjaro for type 2 diabetes, Zepbound for chronic weight management)
• Mechanism — targets two metabolic hormones, GLP-1 and GIP, simultaneously
• Administration — once-weekly subcutaneous injection via prefilled pen, as directed by a prescribing provider
• Key trials — SURMOUNT (weight management) and SURPASS (type 2 diabetes)
• Common side effects reported — mostly mild GI symptoms (nausea, diarrhea, decreased appetite), often easing within a few weeks
• Who prescribes it — only an independent licensed provider; GLP3 Weight Loss does not prescribe, dispense, or sell tirzepatide

Per FDA labeling, tirzepatide for weight management is generally considered for adults with a BMI of 30+ (or 27+ with at least one weight-related condition). It is among the most effective weight-loss medications currently approved.

Tirzepatide is frequently discussed for people with type 2 diabetes or significant insulin resistance, given the glucose-lowering effects reported in trials, and for those who have plateaued on semaglutide.

This information is educational. Whether tirzepatide is appropriate for you is a decision only an independent licensed provider can make. You can also read about semaglutide and the investigational triple agonist retatrutide.